

Provided by:



CCEB Seminar Lecture Series 2023-2024  
2024

**CCEB Seminar Lecture Series 2023-2024 - 5/15/2024 | Stephanie Leonard, PhD | Inequities in Severe Maternal and Neonatal Morbidities**  
**May 15, 2024**  
**9:00 AM - 10:00 AM**

**Target Audience**

This program has been designed for ALL SPECIALTIES

**Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss how to select appropriate targets for intervention to improve public health
- 1 Review statistical techniques (e.g. logistic regression) with appropriate understanding of limitations and assumptions made
- 3 Describe appropriate disease management goals (eg. Blood pressure target) for their individual patients

**Session Educational Objectives**

After completing this educational activity, participants should be able to:

- 1 Describe endorsed measures of severe maternal morbidity and severe term newborn morbidity, including their overlap and shared common causes
- 2 Discuss distal and proximal drivers of inequities in severe maternal and neonatal morbidity in the U.S., with a focus on evidence from California

**Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is not approved for nursing contact hours

**Pharmacists:** This activity is approved for 1.00 contact hours

UAN Number: JA0000324-0000-24-017-L04-P

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

**Acknowledgement of Commercial Support\***

None

For more information, please contact  
Mark Burnett, Mae Phelps  
(215) 898-1708, No phone on file

Mark.Burnett@Pennmedicine.upenn.edu, emae@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Robert Gross, MD	Other Planning Committee Member	Independent Contractor (included contracted research)-Pfizer, Inc. - 03/21/2024
Michael Z David, MD, MS, PhD	Co-Director	Consulting Fee-Glaxo Smith Kline (Relationship has ended)   Grant or research support-Glaxo Smith Kline (Relationship has ended)   Consulting Fee-Johnson & Johnson (Relationship has ended)   Grant or research support-Contrafect (Relationship has ended) - 08/29/2023
David Margolis, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc. (Relationship has ended)   Consulting Fee-Comanche Biopharma   Consulting Fee-Insmed   Consulting Fee-Everest (Relationship has ended)   Consulting Fee-Johnson & Johnson   Grant or research support-Bausch Health a Valeant Pharmaceuticals Co.   Grant or research support-Pfizer, Inc. (Relationship has ended) - 08/30/2023
Mary Putt II, PhD, ScD	Other Planning Committee Member	Other: Support of Statistical Issues in Annual Clinical Trials Conference-Merck & Co   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Eli Lilly   Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Novartis / Amgen   Stocks or stock options, excluding diversified mutual funds of

		a publicly traded company-Roche Pharmaceuticals - 03/18/2024
Alexis Ogdie, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc.   Grant or research support-Janssen Pharmaceuticals (J&J)   Consulting Fee-CorEvitas   Honoraria-Kopa/Twill, Gilead   Grant or research support-AbbVie, Inc.   Grant or research support-Novartis / Amgen   Grant or research support-Pfizer, Inc.   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Glaxo Smith Kline   Consulting Fee-UCB   Consulting Fee-Bristol-Myers Squibb   Consulting Fee-Novartis / Amgen   Consulting Fee-AbbVie, Inc. - 09/20/2023
Ricardo Castillo-Neyra, DVM	Co-Director	Nothing to disclose - 08/07/2023
Sean Hennessy, PharmD	Pharmacy Planner	Consulting Fee-Intercept Pharmaceuticals (Relationship has ended)   Consulting Fee-Urovant Sciences (Relationship has ended)   Consulting Fee-Covis Pharma GmbH (Relationship has ended)   Consulting Fee-Astra Zeneca Pharmaceuticals   Consulting Fee-Novo Nordisk   Consulting Fee-Glaxo Smith Kline   Consulting Fee-Eli Lilly   Consulting Fee-Provention Bio, Inc (Relationship has ended)   Consulting Fee-Bluebird Bio, Inc (Relationship has ended)   Consulting Fee-Amylyx Pharmaceuticals Inc (Relationship has ended)   Consulting Fee-Ipsen (Relationship has ended)   Consulting Fee-i2o (Relationship has ended) - 09/21/2023
Ellen C Caniglia	Co-Director	Nothing to disclose - 08/07/2023
Stephanie A Leonard, PhD	Faculty	Nothing to disclose - 04/23/2024

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected